Bioventus Inc. (BVS) has a consensus analyst rating of Buy, based on 6 analysts covering the stock. Of those, 4 recommend buying, 2 recommend holding, and 0 recommend selling.
The analyst consensus price target for BVS is $13.00, representing a +31.2% upside from the current price of $9.91. Price targets range from a low of $13.00 to a high of $13.00.
